No products in the cart.
Spike(S1+S2)-N501Y mutation vectors and SARS-CoV-2(2019nCoV) Pseudotyped virus
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector and adenovirus for COVID-19 SARS-COV-2 (2019nCOV) spike-N501Y mutation.
SARS-CoV-2 spike-N501Y mutation
The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).
Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike- mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage.
The mutations and deletions information of GeneMedi’s codon-optimized Spike vector for SARS-COV-2 B.1.1.7 lineage in UK COVID-19 pandemic recently:
|
21765-21770 deletion |
Spike-S1 Subunit |
HV 69-70 deletion (Click to more details about HV 69-70 deletion related products) |
Table 1 | All mutations and deletions occur in COVID-19 SARS-COV-2 (2019nCOV) B.1.1.7 lineage
(Click to more details about B.1.1.7 lineage related products).
| Gene | Nucleotide | Amino acid | |
| ORF1ab | C3267T | T1001I | |
| C5388A | A1708D | ||
| T6954C | I2230T | ||
| 11288-11296 deletion | SGF 3675-3677 deletion | ||
| spike | 21765-21770 deletion | HV 69-70 deletion (Click to more details about HV 69-70 deletion related products) | |
| 21991-21993 deletion | Y144 deletion | ||
| A23063T | N501Y (Click to more details about N501Y related products) | ||
| C23271A | A570D | ||
| C23604A | P681H | ||
| C23709T | T716I | ||
| T24506G | S982A | ||
| G24914C | D1118H | ||
| Orf8 | C27972T | Q27stop | |
| G28048T | R52I | ||
| A28111G | Y73C | ||
| N | 28280 GAT->CTA | D3L | |
| C28977T | S235F |
Reference:
1 Gu, Hongjing, Qi Chen, Guan Yang, Lei He, Hang Fan, Yong-Qiang Deng, Yanxiao Wang, et al. 2020. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (6511): 1603–7.
2 Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam S. Dingens, Mary Jane Navarro, et al. 2020. “Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.” Cell 182 (5): 1295–1310.e20.
